Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

123 results about "Sinus inflammation" patented technology

Methods of measuring symptoms of chronic rhinosinusitis

InactiveUS20070226012A1Improvement in treatment of chronicAble to understandComputer-assisted medical data acquisitionSpecial data processing applicationsSigns and symptomsPatient population
A method for diagnosing, assessing, and determining of the efficacy of a treatment regimen for chronic rhinosinusitis is presented. The method comprises collecting subjective information from a patient or patient population in the form of patient entries into a daily diary, wherein the daily diary comprises the patient responses to questions directed to the presence or absence of a group of clinical signs and symptoms related to chronic rhinosinusitis. Based upon the patient responses in the daily diaries, certain of the clinical signs and symptoms are identified for use in the generation of a scoring tool useful in the determination and assessment of the efficacy of a treatment regimen for chronic rhinosinusitis, as well as in the clinical determination of the severity of the symptoms related to chronic rhinosinusitis.
Owner:NARYX PHARMA INC

Compositions comprising azelastine and methods of use thereof

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and / or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and / or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.
Owner:MEDA PHARMA INC

Drug combinations containing pde4 inhibitors and nsaids

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma.The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.
Owner:BOEHRINGER INGELHEIM INT GMBH

Formulations and methods for treating rhinosinusitis

The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
Owner:MYLAN SPECIALTY

Traditional Chinese herbal preparation for treating chronic nasosinusitis

The invention discloses a traditional Chinese herbal preparation for treating chronic nasosinusitis, which consists of gypsum, honeysuckle, chrysanthemum, ligusticum wallichii, radix angelicae, mint, dried tangerine, figwort root, spina gleditsiae, radices sileris, radix rehmanniae, angelica sinensis, pollen, magnolia flower, Siberian cocklour fruit, platycodon grandiflorum, radix bupleuri, radixscutellariae, herba pogostemonis, radix puerariae, bighead atractylodes rhizome and liquorice, the medicines are composited to generate a synergistic effect of all the medicine efficacies, and the preparation has the effects of opening the inhibited lung-energy, dispelling pathogenic wind, clearing liver fire, cooling and activating blood, eliminating stagnation and discharging pus. The traditional Chinese herbal preparation adopts the pharmacological basis on treating chronic nasosinusitis that: by aiming at the etiological pathology of the chronic nasosinusitis, the traditional Chinese herbal preparation prevents bacteria, diminish inflammation, avoid allergic reaction, improve immunity of the organism and microcirculation, and promote tissue cell repair. The preparation of the invention not only is in accordance with the principle of medicine and health syndrome differentiation and treatment in China, but also is supported by modern pharmological study, so the curative effect is obvious; and the preparation has no toxic or side effect, stable long-term effect and convenience for taking, and is worth being popularized.
Owner:NANYANG MEDICAL COLLEGE

New treatment

ActiveUS20170112839A1Modulating CFTR activityDigestive systemRespiratory disorderSinusitisDisease
The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a leukotriene receptor antagonist. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a CFTR potentiator or a CFTR corrector.
Owner:VERONA PHARMA

Methods and compositions for treating siglec-8 associated diseases

ActiveUS20170073413A1Diminished function of cellImpaired cell functionNervous disorderDigestive systemAsthmaAntibody
The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.
Owner:ALLAKOS

Traditional Chinese medicine composition for treating acute sinusitis and preparation method thereof

The invention provides a traditional Chinese medicine composition for treating acute sinusitis and a preparation method thereof. The traditional Chinese medicine composition comprises an oral medicine and an external-use medicine. The oral medicine comprises the following raw materials: fortune eupatorium herb, Chinese angelica, biond magnolia flower, manchurian wildginger, long pepper, small centipeda herb, Siberian cocklour fruit, honeysuckle flower, suberect spatholobus stem, lilac pink herb, ginseng leaves, astragalus root, coptis, gentian root, lycium berry, pueraria root, arctium fruit, prunella spike, feather cockscomb seeds, radix liriopes, dendrobium, silybum marianum, rhizoma polygonati, radix acanthopanacis senticosi and licorice root; and the external-use medicine comprises the following raw materials: the biond magnolia flower, the manchurian wildginger, the long pepper, the small centipeda herb, the Siberian cocklour fruit, perilla leaves, mint, ephedra, lygodium spore, ligusticum root, Yuzhou uniflower swisscentaury root, achyranthes root, cowherb seeds, folium ilicis purpurea, radix bupleuri, cornu bubali, Japanese ampelopsis root, coptis, akebia fruit, tangerine peel, musk and the licorice root. The traditional Chinese medicine composition has the advantages that the efficiency for treating the acute sinusitis is high, the time of taking effect is faster, the pain of a patient can be quickly relieved within a short time, the cure rate is high, and the recurrence rate is low.
Owner:深圳市恒善堂医药有限公司

Method for treating phthisis by inhaling atomized purple garlic liquid

The invention belongs to the technical field of medicine, and relates to a method for treating the phthisis and the respiratory disease by inhaling atomized purple garlic liquid, in particular to a method for treating the phthisis through the extracting solution of purple garlic (the purple garlic liquid) and an atomizer. The purple garlic liquid is extracted at the low temperature and is atomized by the atomizer into ultramicro particles with the diameter being about 0.2 micron, the atomized liquid can fully and evenly adhere to the pulmonary alveoli and the inner walls of the bronchi through the deep breathing and medicine feeding treatment, and due to the fact that the diameter of the atomized liquid is small, the atomized liquid permeates evenly and can reach the focal zone to carry out sterilization and take part in the lung blood microcirculation, and the active ingredient allisatin of the garlic liquid is conveyed along with the blood to kill and restrain bacteria. The method solves the problems that current common oral administration anti-phthisis western medicines are large in side effect and bad in medicine resistance and curative effect and injure the liver and kidneys. The method can be applied to the pneumology department to treat bronchitis, asthma, flu, sphagitis, rhinitis, nasosinusitis and other respiratory diseases besides the phthisis and pneumonia in the pulmonary medicine. The purple garlic liquid is a very good natural medicine, and the method is very good.
Owner:王星明

Chinese medicinal composition for treating chronic sinusitis

InactiveCN102327451AInhibition of secretionRestoring the cleaning function of ciliaRespiratory disorderPlant ingredientsAdjuvantBaical Skullcap Root
The invention belongs to the technical field of traditional Chinese medicines and discloses a Chinese medicinal composition for treating chronic sinusitis. The Chinese medicinal composition is prepared from the following raw material medicaments in part by weight: 25 to 35 parts of honeysuckle flower, 15 to 25 parts of biond magnolia flower, 10 to 20 parts of siberian cocklour fruit, 10 to 20 parts of angelica dahurica, 7 to 17 parts of baical skullcap root, 10 to 20 parts of Chinese thorowax root, 10 to 20 parts of gentian, 7 to 17 parts of rhizoma anemarrhenae, 15 to 25 parts of astragalus,5 to 15 parts of manchurian wildginger and 5 to 15 parts of liquoric root. The Chinese medicinal composition has the advantages that: chief medicaments, deputy medicaments, adjuvant medicaments and envoy medicaments have appropriate compatibility; the selected medicaments are excellent and combined; the Chinese medicinal composition has the effects of clearing heat and drying damp, diffusing and freeing the orifices, tonifying vitality and strengthening exterior, and strengthening body resistance and eliminating evil, can quickly remove sinus inflammation, restrain mucosal secretion and quickly eliminate clinical symptoms, has the effects of reconstructing damaged nasal mucosa and recovering the cleaning function of nasal mucosa cilia, consolidates the curative effect, does not have adverse effects after being taken for a long time, is safe to take, has an exact curative effect and is worth of clinical popularization.
Owner:陈群英

Preparation for treating rhinitis containing active ingredients of cannabinoid (CBD) and preparation method thereof

The invention discloses a preparation for treating rhinitis containing active ingredients of cannabinoid (CBD) and a preparation method thereof. The preparation for treating rhinitis containing the active ingredients of cannabinoid (CBD) is prepared from the following raw materials in percentage by mass: 2-20% of cannabinoid (CBD), 0.2-1% of a rhizoma gastrodiae extract, 0.1-0.5% of a pseudo-ginseng extract, 0.1-0.6% of a rhizoma polygonati extract, 2-10% of hydrogenated castor oil with polyoxyethylene, 1-5% of 1,2-propanediol, 1-10% of glycerine, 1-10% of rapeseed oil, 0.2-1% of sorbic acid, and the balance of water; and the sum of the raw materials is 100%. The preparation for treating rhinitis is capable of treating symptoms of various kinds of rhinitis, including acute rhinitis, chronic rhinitis, sinusitis and the like. The preparation for treating rhinitis contains cannabinoid (CBD) as an active component, and combines auxiliary effects of nano-emulsion; so that, the functions of the cannabinoid (CBD) are enhanced with stability improved. Moreover, the cannabinoid (CBD) is used in cooperation with the rhizoma gastrodiae extract, the pseudo-ginseng extract and the rhizoma polygonati extract so as to synergistically take an effect; and thus, the prepared preparation for treating rhinitis is capable of uniformly playing the maximum effects, allowing rapid absorption, yielding faster results after administration, convenient to use, and easy for an affected area or a lesion to absorb. The preparation for treating rhinitis containing active ingredients of cannabinoid (CBD) is a medicine for external application.
Owner:云南辰锦威生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products